Clinical Study of Autologous Natural Killer Cells in Multiple Myeloma
Status:
Active, not recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
Multiple Myeloma (MM) is a lethal disease and at present no available treatment method seems
to prevent the disease from progressing or relapsing in the long term. NK cells have a
relatively high cytotoxic capacity and an anti tumour effect, suggesting a potential as a
treatment of MM.This is a phase I, first-in-human, therapeutic exploratory study, where no
benefits for the patients can be guaranteed. However, the theoretical implication is that the
infused cells may have a positive antitumour effect for the participating individuals.